Skip to NavigationSkip to content

Pharmafile.com's weekly COVID-19 news round-up

Published on 03/06/20 at 10:48am
Photo by CDC

COVID-19 treatments dominate the news this week as Russia is set to start its roll out of the anti-viral drug Avifavir to coronavirus patients, while the UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s remdesivir and found the drug to have a tentatively “favourable” profile.

Multiple European countries have also rejected the use of hydroxychloroquine in patients suffering from coronavirus, while the US has given $1 billion to AstraZeneca to advance the development and production of the vaccine they are creating in collaboration with the Oxford University.

1. US donates $1 billion to Oxford University's COVID-19 vaccine in exchange for 300 million dosesPublished 29/05/20

The US has given $1 billion to AstraZeneca to advance the development and production of the vaccine they are creating in collaboration with the Oxford University.

2. Cleaning staff excluded from GSK's £1.5k COVID-19 employee bonusPublished on 26/05/20

UK pharma giant GlaxoSmithKline has pledged to pay a cash bonus of £1,500 to staff continuing to work during the COVID-19 pandemic, acknowledging the increased risk they face for maintaining research and production operations during this dangerous time.

3. Russia to begin administering anti-viral COVID-19 drug next weekPublished 01/06/20

Russia will start its roll out of the anti-viral drug Avifavir (favipiravir) to COVID-19 patients next week, according to the Russian Direct Investment Fund (RDIF).

4. European countries reject hydroxychloroquine treatments for COVID-19Published 28/05/2020

Multiple European countries have rejected the use of hydroxychloroquine in patients suffering from coronavirus, due to a lack of evidence that it is effective.

5. First ever benefit-risk analysis is "favourable" for remdesivir as COVID-19 treatmentPublished 29/05/20

The UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s remdesivir, one of the leading hope in the treatment of COVID-19, noting that it found the drug to have a tentatively “favourable” profile.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches